Pyrotinib and Capecitabine Combo Improved PFS Compared to Lapatinib Plus Capecitabine for HER2...
Dec 19, 2023
The combination of pyrotinib plus capecitabine resulted in a statistically significant improvement in progression-free survival compared with lapatinib (Tykerb) plus capecitabine as treatment of patients with previously treated HER2-positive metastatic breast cancer, according to data published in The Lancet Oncology. The pyrotinib-plus-capecitabine combination also maintained a tolerable safety profile, presenting itself as an alternative treatment option for this cohort of patients after trastuzumab (Herceptin) and chemotherapy. “The findings from this study suggest that pyrotinib plus capecitabine is a novel treatment for patients with HER2-positive metastatic breast cancer after trastuzumab and chemotherapy, and is an alternative option to the current treatment landscape, particularly in regions with scarce access to HER2-directed drugs,” wrote the investigators.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…